Innovate UK

Constructive Bio is a biotechnology company that rewrites genomes to turn living cells into biofactories for sustainable materials and therapeutics. By controlling the genetic sequence, it enables the biosynthesis of enzymes, pharmaceuticals, and biomaterials while exploring chemical space beyond natural biology. The approach includes developing virus-resistant organisms and supporting next-generation bioprocesses and biopharmaceuticals.

LinkGevity is a biotechnology company specializing in drug discovery, with a focus on longevity and age-related diseases. It operates an AI-powered platform designed to expedite the development of life-saving medications. By combining AI and pharmaceutical expertise, the company analyzes extensive datasets to predict and identify promising drug candidates, aiming to extend healthy lifespan and bring innovative treatments to market more swiftly.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Lant Medical is a health technology company specializing in the development of non-antibiotic treatments for Helicobacter pylori (H. pylori) infections. Their innovative therapy targets the root cause of the infection and its associated symptoms, providing an effective monotherapy or complement to existing treatments. This enables healthcare professionals to manage H. pylori infections more efficiently.

Keltic Pharma Therapeutics enhances drug discovery through innovative scientific research, resulting in a healthier future.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

Epitopea is a transatlantic biotechnology company focused on developing immunotherapies that target a novel class of tumor‑specific antigens. Using a proprietary pipeline that combines immunopetidomics, mass spectrometry, genomics and bioinformatics, the company identifies conserved, aberrantly expressed antigens hidden in cancer’s ‘junk’ DNA. These Cryptigen TSAs are shared across patients with the same cancer indication, allowing therapies to selectively eliminate malignant cells while sparing healthy tissue, with the goal of providing durable, low‑side‑effect treatments.

Theolytics Limited is a clinical-stage biotechnology company based in Oxford, United Kingdom, specializing in the development of oncolytic viral therapies to combat cancer. Founded in 2017, Theolytics utilizes a phenotypic screening platform that facilitates the discovery and development of effective, targeted therapeutic candidates designed for intravenous delivery. The company's innovative approach is aimed at creating category-changing cancer treatments that can address both solid and liquid tumors. In addition to advancing its internal pipeline of programs, Theolytics is also forming strategic partnerships to enhance and expedite the development of its therapeutic offerings, ultimately striving to provide innovative care options for patients.

Awen Oncology is a pre-clinical stage pharmaceutical company focused on developing novel cancer therapies. It specializes in targeting 'developmentally-silent oncogenic drivers', which are genes that contribute to cancer growth but are not typically targeted by existing treatments. The company's approach combines expertise in cell and molecular biology with advanced structural biology and in-silico drug screening to rapidly and efficiently identify and develop effective cancer treatments.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

BiVictriX Therapeutics Ltd. is a drug discovery and development company based in Alderley Edge, United Kingdom, focused on creating bispecific antibody drug conjugates to address unmet medical needs in blood cancer. Established in 2016, the company leverages its proprietary Bi-Cygni technology to develop innovative therapies for various types of cancers, including Acute Myeloid Leukaemia. BiVictriX specializes in oncology and haematological malignancies, offering a range of services that encompass biotherapeutics, immunotherapy, antibody research, and drug development. The company aims to advance its pharmaceutical products through rigorous development processes to improve treatment outcomes for patients with serious medical conditions.

IXICO plc, established in 1995 and headquartered in London, specializes in providing data analytics services to the global biopharmaceutical industry. The company focuses on the collection, analysis, management, and reporting of data generated during clinical studies, with a particular emphasis on neurological diseases. IXICO's key technologies include Assessa, a digital platform for clinical decision support, and TrialTracker, a comprehensive imaging service workflow management system. The company's end-to-end imaging services are primarily applied in the fields of Alzheimer's, Parkinson's, Huntington's, multiple sclerosis, cerebrovascular, and progressive supranuclear palsy diseases. IXICO's services are utilized to select patients for clinical trials, assess drug safety and efficacy, and for post-marketing surveillance. The company works with pharmaceutical companies, biotech firms, academia, and medical charities worldwide.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Concr is a mission-driven techbio company that uses established methods from astrophysics to predict patient outcomes and treatment response to cancer therapies. The approach enables iterative learning from fragmented data across the drug development and clinical journey, producing accurate multi-modal tumor models without relying on large, homogeneous datasets. Its cloud-native platform FarrSight supports computational simulation of clinical trials, prediction of therapeutic response and biomarkers, and standard bioinformatics analyses. Headquartered in London with a wholly owned subsidiary in Brisbane, Concr provides a cloud-based system that identifies optimal treatments for individuals, reduces resistance, and offers patient-specific progression insights and evidence-based treatment plans to guide proactive therapy.

Mesenbio is a preclinical biopharmaceutical company based at the University of York, specializing in cell-derived therapies. It has developed a unique technique known as Cell Line Extracellular Vesicle Release (CLEVR), which aims to enhance the treatment pipeline by addressing significant challenges in extracellular vesicle therapy. The company focuses on creating innovative treatments, including a novel therapy for arthritis derived from engineered human stem cells. By unlocking the potential of extracellular vesicles, Mesenbio seeks to transform medical approaches to musculoskeletal diseases, thereby providing more effective therapeutic options.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Pathios Therapeutics is an early-stage biotech company based in Oxford, United Kingdom, focused on developing therapies for autoimmune diseases and cancer. Founded in 2017, the company specializes in creating small molecule inhibitors that target the pH-sensing G protein-coupled receptor GPR65. These inhibitors are designed to counteract the immunosuppressive effects of immune cells, such as tumor-associated macrophages, which are influenced by the acidic environment often found in tumors. By leveraging a deep scientific approach and human genetic insights, Pathios Therapeutics aims to generate novel therapeutics for advanced solid tumors and other unmet medical needs.

ThirtyFiveBio is a biotechnology company developing novel genetically and pharmacologically validated protein modulators for treating severe gastrointestinal diseases.

Founded in 2012, Stablepharma specializes in developing processes for vaccine stabilization. Its flagship product, Stablevax, enables precise dosage pre-loading into syringes at manufacture, eliminating wastage. The company's technology platform converts existing vaccines and diagnostics into thermostable products, addressing global cold chain challenges.

AstronauTx focuses on restoring healthy function of astrocytes, a type of brain cell crucial for neuronal health and blood-brain barrier integrity. Its primary goal is to develop treatments targeting astrocyte dysfunction in dementias like Alzheimer's disease.

Intellegens is a company that specializes in applying machine learning to enhance innovation across various industries, including materials, chemicals, and manufacturing. Its flagship product, Alchemite™, was initially developed at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional machine learning methods often struggle. This platform allows scientists, engineers, and analysts to optimize formulations, products, and processes while significantly reducing the number of experiments required, often by up to 90%. Alchemite™ features a user-friendly web interface and powerful graphical analysis tools, and it can be seamlessly integrated into existing data science workflows. The technology has been successfully applied in multiple fields, including drug discovery, materials development, and additive manufacturing, thereby enabling clients to extract greater value from their data and accelerate their development timelines.

Peptimatrix is a biotechnology company specializing in the development of an innovative, animal-free 3D cell culture platform. Utilizing a peptide hydrogel technology, the company aims to reduce and replace the use of animals and animal-derived products in drug development and research. By combining expertise from matrix biologists, cancer scientists, toxicologists, and biomaterial engineers, Peptimatrix offers a more reproducible, reliable, and ethical alternative to traditional cell culture methods. The company's mission is to provide researchers with a better way to model development and disease.

Autolomous develops pragmatic software solutions for cell and gene therapy manufacturers. Its platform, autoloMATE®, offers end-to-end solutions including resource scheduling, electronic batch records management, insights reporting, review, and release activities. The platform aligns with US FDA, EU EMA & UK MHRA guidance and is certified ISO 27001:2013 (information security), ISO 9001:2015 (quality management), and ISO 14001:2015 (environmental management).

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Lindus Health is a clinical research organization that specializes in managing end-to-end clinical trials for healthcare and biotechnology companies. The company offers services such as ethics and IRB submissions, trial monitoring, data management, biostatistics, regulatory affairs, and payor relations. Lindus Health employs an in-house team of clinicians and researchers to accelerate the clinical trial process using its proprietary software platform, Curebase OS, which automates workflows and reduces manual inefficiencies. The company also leverages real-world patient data for precise participant recruitment and smarter trial design, aiming to make clinical trials faster and more cost-effective while improving patient treatment outcomes.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

DeepMirror develops AI-driven drug design software that combines human expertise with artificial intelligence. Its platform aims to help chemists focus on the most promising drug candidates by simplifying complex data analysis workflows, enabling more efficient drug molecule discovery and development.

LightOx is a biotechnology company focused on developing innovative molecular tools and light-activated therapeutics for cancer treatment. The company offers a unique range of fluorescent probes that are smaller than existing commercial options, allowing for versatile use in imaging, therapeutics, and assay development. These probes can function as freely-moving agents within cells or be coupled with flexible linkers to provide specificity for various research applications. LightOx is dedicated to improving patient outcomes by creating targeted drug compounds that selectively eliminate tumor cells while minimizing damage to surrounding healthy tissues. This approach aims to enhance the efficiency of cancer treatment and contribute to better long-term health for patients.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

EnsiliTech is a biopharmaceuticals company focused on preserving the integrity of vaccines and other biological materials. The company has developed a novel ensilication technology that utilizes protective silica nanoshells to shield vaccine components from environmental degradation. This innovative approach aims to prevent vaccine spoilage, thereby enhancing the shelf-life of these critical biological products. By improving the stability and accessibility of vaccines, EnsiliTech seeks to reduce waste and contribute to global vaccination efforts, ensuring that more people can benefit from life-saving immunizations.

Healthera Ltd., established in 2015 and headquartered in Cambridge, UK, specializes in developing digital health solutions. Its flagship product, Healthera, is a pharmacy-integrated medication management app that offers automatic prescription reminders, smart labelling, scheduling, health condition tracking, and professional advice from pharmacists. Additionally, Healthera operates a healthcare marketplace that connects patients with local pharmacies and GPs, enabling faster medicine delivery and personalized care. The company partners with over 1000 pharmacies and Clinical Commissioning Groups (CCGs) across the UK, reaching over 20 million people. Healthera's technology is accredited by NHS Digital and aims to improve prescribing efficiency, patient experience, and reduce wastage within the NHS.

The Medicines Discovery Catapult is the centre of national expertise for the discovery of medicines.

iEthico specializes in digital technology for streamlining pharmaceutical sourcing. Its automated cloud-based service tracks data, alerts users to medicine shortages, and connects them to reliable sources. The MHRA-approved platform also automates regulatory processes, saving pharmacies time and effort. After successful market testing, the solution is now being rolled out nationwide across community and NHS Trusts in the UK.

LabGenius Ltd is a biopharmaceutical company based in London, United Kingdom, focused on discovering and developing new protein therapeutics to address unmet medical needs, including conditions like Inflammatory Bowel Disease. Founded in 2012, the company utilizes a machine learning-driven evolution engine and a robotic platform known as EVA, which is capable of designing, conducting, and learning from its own experiments. This innovative approach integrates advanced technologies from synthetic biology, robotics, and machine learning, enabling the engineering of protein drugs with enhanced properties such as protease stability and tissue penetration. By leveraging these cutting-edge methodologies, LabGenius aims to provide physicians with access to novel protein therapeutics that are developed through automation and intelligent design.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Aten Therapeutics specializes in developing novel therapeutic antibodies targeting fundamental control pathways associated with major diseases. Their experienced management team aims to extend and improve patients' lives by creating powerful new treatments.

AMPLY Discovery uses machine learning and synthetic biology to mine large biological datasets and identify novel drug and nutraceutical candidates. The company combines an in silico and in vitro platform to discover first-in-class molecules and to tackle cancer, metabolic diseases, and multidrug-resistant infections. It develops a drug discovery studio that leverages artificial intelligence to digitize life’s natural diversity and to identify putative drug candidates based on function, enabling researchers to pursue new therapeutic molecules for hard-to-treat diseases.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Awakn Life Sciences is a clinical-stage biotechnology company dedicated to developing and delivering innovative psychedelic medicine aimed at treating addiction, with a primary focus on Alcohol Use Disorder (AUD). The company comprises a multidisciplinary team of chemists, scientists, psychiatrists, and psychologists who are working to create the next generation of psychedelic drugs and therapies, as well as the technologies that enable their use. Recognizing the inadequacies of current treatment options for AUD, Awakn aims to provide breakthrough therapeutics for individuals suffering from addiction, addressing a significant medical need both in the United States and internationally.

DeepMirror develops AI-driven drug design software that combines human expertise with artificial intelligence. Its platform aims to help chemists focus on the most promising drug candidates by simplifying complex data analysis workflows, enabling more efficient drug molecule discovery and development.

Metallo Bio's focus is on the development of two lead chemicals that represent a pioneering new class of antibiotics, with the goal of addressing the rising issue of antimicrobial resistance.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Founded in 2018 by industry veterans in neuroscience drug discovery, NRG Therapeutics is a biotechnology company dedicated to developing therapeutic approaches that restore mitochondrial function. Their primary focus is slowing or halting the progression of neurodegenerative diseases like Parkinson's and Alzheimer's through innovative drug discovery.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

Eleven Therapeutics is a biotechnology company pioneering AI-driven medicinal nucleic acids. It specializes in developing extended durability mRNA therapeutics, targeting unmet medical needs in metabolic, endocrinologic, and infectious diseases.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

Chromatwist develops innovative fluorescent dyes that become visible under UV light. Their patented technology platform enables the creation of fluorophores used in bio-sensing (like flow cytometry) and bio-imaging (such as multiphoton microscopy) within the healthcare sector.

Glamorous AI develops an artificial intelligence driven drug discovery platform that accelerates pharmaceutical research by leveraging prior experimental results to identify and optimize chemical scaffolds, predict activities, and screen ultra-large chemical libraries. The platform addresses low-data, sparse, and noisy datasets, enabling the discovery of novel compounds and potential therapeutics.

Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in stabilization technology solutions for the pharmaceutical and biotech sectors. Founded in 2006, Arecor utilizes its innovative formulation technology platform to enhance the commercial value and utility of proteins across various applications, including vaccines and therapeutic proteins. The company develops products targeting infectious diseases, diabetes, oncology, immunology, and hormone replacement therapies. It focuses on reformulating existing therapies to improve their stability and efficacy, enabling self-administration for patients through pre-filled syringes and injection pens. Notably, Arecor works on high-concentration formulations of antibodies, such as Trastuzumab and Rituximab, to improve treatment for conditions like breast cancer and non-Hodgkin’s lymphoma. Additionally, Arecor creates stable liquid formulations for vaccines and biological therapies, addressing challenges in degradation and stability. Through partnerships with leading pharmaceutical companies, Arecor aims to deliver advanced reformulations that enhance treatment options for patients.

Senisca is a senotherapeutics company established in 2020, focused on developing anti-aging oligonucleotide therapeutics. The company aims to provide innovative pharmaceutical treatments for age-related chronic diseases by creating a new generation of oligonucleotide-based interventions. These therapeutics target the underlying mechanisms of aging, restoring the ability of cells to regulate gene expression effectively. By rejuvenating aged cells, Senisca seeks to improve healthspan and address both the diseases and aesthetic manifestations of aging, ultimately enabling individuals to live healthier for longer periods.

Founded in 2015 and based in Cambridge, UK, Camallergy is a biopharmaceutical company focused on developing innovative treatments for food allergies. Its lead product is an oral immunotherapy designed to provide significant protection against peanut allergy within just three months.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

Datalase Ltd., based in Widnes, United Kingdom, is a leading provider of materials for laser coding and marking of products and packaging. The company specializes in developing innovative materials that can be incorporated into inks, coatings, and varnishes, enabling high-speed, in-line digital printing of variable information with lasers. This technology allows for late-stage customization on outercases, products, and primary packaging across various markets, including pharmaceuticals, FMCG, food and beverage, electronics, cosmetics, and tobacco. Datalase's solutions are used to print date and lot codes, 2-D data matrix codes, barcodes, images, and graphics. The company operates through a partner network in Europe, the United States, and Asia, and has strategic partnerships with SATO and PARC. Originally incorporated in 1987 as Sherwood Technology Ltd., the company changed its name to Datalase Ltd. in January 2006.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

4D Medicine specializes in creating innovative solutions for the targeted and controlled regeneration of human tissue through the development of degradable, implantable medical devices. Utilizing novel photopolymer materials, the company is advancing a range of products that are currently undergoing regulatory clearance with the Food and Drug Administration. These resorbable medical devices aim to enhance patient outcomes in various applications, including musculoskeletal surgery, soft tissue repair, and drug delivery. By focusing on regulatory approval and effective medical applications, 4D Medicine seeks to provide valuable options for medical device suppliers and healthcare providers.

NovaBiotics Ltd. is a clinical-stage biotechnology company focused on designing and developing first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. Its lead product, Novexatin (NP213), is a topical treatment for fungal nail infections, affecting over 10% of the global population.

Intellegens is a company that specializes in applying machine learning to enhance innovation across various industries, including materials, chemicals, and manufacturing. Its flagship product, Alchemite™, was initially developed at the University of Cambridge and is designed to train deep neural networks using sparse and noisy data, where conventional machine learning methods often struggle. This platform allows scientists, engineers, and analysts to optimize formulations, products, and processes while significantly reducing the number of experiments required, often by up to 90%. Alchemite™ features a user-friendly web interface and powerful graphical analysis tools, and it can be seamlessly integrated into existing data science workflows. The technology has been successfully applied in multiple fields, including drug discovery, materials development, and additive manufacturing, thereby enabling clients to extract greater value from their data and accelerate their development timelines.

Kuano Ltd is a London-based company that specializes in providing quantum and artificial intelligence solutions for molecular design, particularly in the fields of drug discovery and development. Founded in 2020, Kuano has developed a unique discovery platform that integrates quantum simulation with AI-led chemistry, enabling the design of effective inhibitors by analyzing the mechanisms of target enzymes. This innovative approach allows for faster and more efficient development of drug candidates, enhancing the quality of new pharmaceuticals while simultaneously reducing the time required for discovery. The company's solutions are applicable across various sectors, including pharmaceuticals, crop protection, and industrial chemistry.

Medwise.ai operates a customizable search platform that uses natural language processing and artificial intelligence technologies to provide clinical decision support for doctors. Its real-world data offers insights to various healthcare stakeholders, enabling doctors to organize medical knowledge and enhance patient care outcomes.

Vamstar is a company that operates a B2B healthcare supply chain platform aimed at streamlining sourcing and procurement processes for medical device and pharmaceutical companies. The platform utilizes machine learning to capture demand for medical device and pharmaceutical products and services globally, matching this demand with suppliers worldwide. This enables customers to optimize their sourcing and procurement processes, reduce costs, and improve access to essential healthcare products and services. Vamstar's platform aggregates over $2 trillion of global demand across more than 70 countries, providing real-time analytics to facilitate transactions between buyers and suppliers. The company has onboarded some of the world's most innovative healthcare companies and continues to expand its capabilities in the digital marketplace.

Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Lunac Therapeutics develops advanced oral anticoagulant medicines designed to prevent and treat life-threatening thrombotic events. The treatments seek to balance efficacy with safety by minimizing bleeding risk while preserving therapeutic effect, enabling clinicians to manage high-risk patients with safer dosing strategies.

Ixaka is a UK-based biotechnology company focused on developing advanced cell-based therapeutics to treat serious diseases. Its proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and modifying them within the body to improve their action, with potential applications across oncology, cardiovascular, neurological, ocular diseases, and genetic disorders.

Freeline Therapeutics is a clinical-stage biotechnology company specializing in systemic adeno-associated virus (AAV)-based gene therapies. Its pipeline includes FLT180a for hemophilia B, FLT190 for Fabry disease, FLT201 for type 1 Gaucher disease, and FLT210 for hemophilia A, all in various stages of clinical trials.

The Cell and Gene Therapy Catapult is a UK-based centre of excellence dedicated to advancing the cell and gene therapy sector globally. Supported by Innovate UK, it aims to facilitate the translation of early-stage research into commercially viable therapies. With over 120 experts and state-of-the-art laboratories at Guy's Hospital in London, CGT Catapult is building a £55m large-scale manufacturing centre to accelerate market access for these therapies.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Nanna Therapeutics Limited, established in 2012 and headquartered in Cambridge, UK, is a biotechnology company focused on developing drugs for age-related diseases such as mitochondrial, neurodegenerative, cardiovascular/metabolic, joint/tissue diseases, and cancer. As of April 2020, the company operates as a subsidiary of Astellas Pharma Europe Ltd. Nanna Therapeutics employs a unique approach by targeting fundamental cellular processes to create innovative treatments for these conditions, with a particular emphasis on mitochondria, the energy source in every cell. The company's proprietary drug discovery platform, TIME (Totally Integrated Medicines Engine), combines advanced technologies like microfluidics and artificial intelligence to accelerate drug development and disrupt traditional methods of creating new medicines.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

A UK pharmaceutical development company, AKL Research & Development Ltd (AKLRD) is committed to transforming patient’s lives through innovative solutions that meet unmet needs.AKLRD is developing novel therapeutics for inflammatory diseases with a high unmet need, including osteoarthritis, Alzheimer’s, rheumatoid arthritis & scleroderma, a rare connective tissue disease.

Roslin Cells is the parent company of Roslin Cell Therapies. Based in Edinburgh, UK Roslin Cell Therapies has a wealth of expertise, capabilities and industry recognition in process translation to GMP, development, optimization, scale up and the GMP manufacture of Cell Therapy and Advanced Therapy Medicinal Products (ATMPs).

Medherant is a clinical-stage company focused on transdermal drug delivery for pain and central nervous system conditions. Its TEPI Patch uses an adhesive technology designed to enable higher drug loading, controlled release, and compatibility with a wide range of drug types, addressing limitations of conventional patches and reducing issues seen with creams and gels. The platform emphasizes water resistance and efficient drug delivery to improve patient comfort and therapeutic effectiveness. Medherant originated from academic work at the University of Warwick led by Professor David Haddleton and was founded in 2014 in Coventry, United Kingdom, with a goal to commercialise transdermal delivery platforms that broaden the applicability of transdermal administration for diverse medicines.

Optibrium is a software company that specializes in providing innovative solutions for small molecule design, optimization, and data analysis, aimed at enhancing the drug discovery process. Founded in 2009 and headquartered in Cambridge, UK, with an additional office in Boston, US, the company’s flagship product, StarDrop, is a comprehensive and user-friendly software suite that facilitates the integration of data, predictive modeling, and decision-making in research. This tool enables users to streamline their workflow from data analysis to compound synthesis, thereby increasing the speed and efficiency of drug discovery. Optibrium collaborates with a diverse range of clients, including leading pharmaceutical companies, biotech firms, and academic institutions, to continuously develop new technologies and improve productivity in drug development.

Storm Therapeutics Limited is a biotechnology company based in Cambridge, United Kingdom, focused on discovering and developing small molecule drugs that target RNA-modifying enzymes for cancer treatment and other immune diseases. Incorporated in 2015 and previously known as Iceni Therapeutics Limited, the company utilizes its drug discovery and RNA analytics platform to modulate RNA modifying enzymes, identifying novel targets and first-in-class drug candidates. Storm Therapeutics aims to provide innovative therapies against RNA epigenetic targets, addressing various conditions including oncology, inflammation, viral infections, and central nervous system diseases.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services. Founded in 2015, the company provides a range of preclinical screening services, with a particular focus on ion channel testing. Its offerings include cardiac safety screening, neuroscience assays, and translational assays, aimed at supporting pharmaceutical and bioscience clients globally. Metrion Biosciences employs highly skilled electrophysiology techniques and offers flexible business models, including fee-for-service and collaborative options. This versatility allows the company to cater to various medicinal chemistry optimization programs, ensuring comprehensive support throughout the drug discovery process.

Ubiquigent Limited is a biotechnology company based in Dundee, United Kingdom, founded in 2009. It specializes in the development and supply of high-quality reagents, kits, and drug discovery assay development services, focusing on the ubiquitin and ubiquitin-like signaling systems. The company provides protein degradation-focused drug discovery services and designs novel deubiquitylase (DUB) enzyme inhibitors as potential therapeutics for addressing unmet medical needs. Ubiquigent collaborates with both academic and pharmaceutical researchers, supporting fundamental scientific discovery and the exploration of innovative drug candidates targeting DUBs. Its hybrid business model emphasizes the generation of intellectual property while maintaining an internal pipeline of drug discovery programs aimed at optimizing compounds for critical therapeutic areas.

Almac Group is a global contract development and manufacturing organization that provides a comprehensive suite of services to pharmaceutical and biotechnology companies. Its offerings span research and development, biomarker discovery, active pharmaceutical ingredient production, formulation development, clinical trial supply, interactive voice response system technology, commercial‑scale manufacturing, and companion diagnostic development. Founded more than four decades ago, the privately held company employs over 4,500 professionals and is headquartered in Craigavon, Northern Ireland. Almac operates facilities across the United Kingdom, Ireland, the United States (Pennsylvania, North Carolina, California), and Asia (Singapore, Tokyo), and continually invests in advanced capabilities such as biocatalytic API synthesis, clinical trial data management, and the clinical supply chain. The organization also encompasses specialized units, including Almac Sciences, which offers analytical testing for drug substances and products, and Almac Discovery, a research‑driven oncology company focused on early‑stage drug discovery.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Phico Therapeutics is a biotechnology company focused on developing innovative antibiotics to combat antibacterial resistance. Its proprietary platform, SASPject, delivers anti-bacterial proteins to specific bacterial species using targeted non-delivery vehicles. The company's pipeline includes treatments for Pseudomonas aeruginosa, Klebsiella pneumoniae, Escherichia coli, and Staphylococcus aureus.

Arecor Limited is a biopharmaceutical company based in Cambridge, United Kingdom, specializing in stabilization technology solutions for the pharmaceutical and biotech sectors. Founded in 2006, Arecor utilizes its innovative formulation technology platform to enhance the commercial value and utility of proteins across various applications, including vaccines and therapeutic proteins. The company develops products targeting infectious diseases, diabetes, oncology, immunology, and hormone replacement therapies. It focuses on reformulating existing therapies to improve their stability and efficacy, enabling self-administration for patients through pre-filled syringes and injection pens. Notably, Arecor works on high-concentration formulations of antibodies, such as Trastuzumab and Rituximab, to improve treatment for conditions like breast cancer and non-Hodgkin’s lymphoma. Additionally, Arecor creates stable liquid formulations for vaccines and biological therapies, addressing challenges in degradation and stability. Through partnerships with leading pharmaceutical companies, Arecor aims to deliver advanced reformulations that enhance treatment options for patients.

Sentinel Oncology Limited is a drug discovery company based in Cambridge, United Kingdom, established in 2005. The company is focused on developing and commercializing therapeutics aimed at treating cancer, particularly for patients with unmet medical needs. Sentinel Oncology utilizes small molecule approaches to target the microenvironment of solid tumors. Its research and development pipeline includes programs such as Checkpoint Kinase 1, which activates in response to DNA damage and replication stress, and a novel drug targeting S6K1 to address metastatic breast cancer. Additionally, the company is advancing a strategy called "Targeted Synergy," designed to enhance the therapeutic index by delivering drug effects directly to the tumor. Sentinel Oncology aims to create high-quality drug candidates for collaboration with the biotechnology and pharmaceutical industries.

Vitamica Ltd is a diagnostic technology company based in Bristol, United Kingdom, founded in 2018 as a spin-out from the University of Bristol. The company specializes in rapid antimicrobial susceptibility testing (AST) that enables the swift identification of pathogenic bacteria and their resistance to antibiotics. By utilizing advanced optical technology, Vitamica's innovative approach detects nanoscale fluctuations in live bacteria, providing clinicians with critical information to guide antibiotic treatment decisions. With a growing portfolio of intellectual property, Vitamica aims to make significant contributions to the healthcare, veterinary, and pharmaceutical sectors through its novel diagnostic methods.

MGB Biopharma is a UK-based biopharmaceutical company developing novel anti-infective medicines. It focuses on small molecules with specific antibacterial effects, targeting resistant bacteria using its proprietary DNA Minor Groove Binders technology.

Physiomics Plc is a consulting firm based in Oxford, United Kingdom, specializing in services for pharmaceutical companies in the realms of quantitative pharmacology and computational biology. Established in 2001, the company utilizes its proprietary Virtual Tumour predictive software to offer modeling, simulation, and data analysis services, primarily focused on oncology research and development. By combining systems biology with advanced mathematical techniques, Physiomics aims to optimize dosing and scheduling of oncology drugs during pre-clinical and clinical trials, enhancing the efficacy of drug combinations and streamlining the overall drug development process. The company's operations extend across the United Kingdom, the European Union, Switzerland, and the United States, with a commitment to advancing personalized medicine through innovative technology.

Symbiosis Pharmaceutical Services Limited is a contract manufacturer specializing in sterile pharmaceuticals for clinical trials, established in 2011 in Stirling, United Kingdom. The company addresses the growing global demand for niche sterile manufacturing by providing filling and finishing services tailored to the needs of biotech and specialty pharmaceutical companies. Its purpose-built facility is designed to accommodate both biologic and small molecule production, focusing on small-scale injectable products. Symbiosis distinguishes itself by offering rapid access to manufacturing slots and quick release of drug products, enabling clients to meet tight timelines effectively. With a commitment to maintaining regulatory compliance, Symbiosis supports its clients in navigating the complexities of drug product development and supply.

Metrion Biosciences Ltd is a contract research organization based in Cambridge, United Kingdom, specializing in drug discovery services. Founded in 2015, the company provides a range of preclinical screening services, with a particular focus on ion channel testing. Its offerings include cardiac safety screening, neuroscience assays, and translational assays, aimed at supporting pharmaceutical and bioscience clients globally. Metrion Biosciences employs highly skilled electrophysiology techniques and offers flexible business models, including fee-for-service and collaborative options. This versatility allows the company to cater to various medicinal chemistry optimization programs, ensuring comprehensive support throughout the drug discovery process.

Eagle Genomics is a life sciences software company that provides data management and analytics platforms for genomics and related fields. Its solutions enable management, orchestration and exploitation of genomics and other life sciences data, turning diverse datasets into usable data assets and supporting end-to-end workflows from data integration and curation to analysis, visualization and sharing. The company combines biology, bioinformatics, data science, and enterprise software engineering to help pharmaceutical, consumer goods, and agricultural technology organizations shorten research cycles and improve decision making. Its offerings cover next-generation sequencing data management and analysis, cloud-based bioinformatics, biomarker discovery, microarray analysis, and pipeline design, as well as on-demand consulting and tools for managing research data. Headquartered in Cambridge, United Kingdom, with an international footprint, Eagle Genomics emphasizes building an enterprise information architecture for the genomics era, enabling customers to realize the value of digital assets and enhance productivity across R&D programs.

Founded in 2001, Domainex Ltd. is a UK-based biotechnology company specializing in contract research and manufacturing services for drug discovery. It offers a range of services including medicinal chemistry, computational chemistry, protein expression, assay development, and DMPK analysis. The company also focuses on developing treatments for inflammatory diseases like rheumatoid arthritis.

Cobra Biologics, founded in 1992 and based in Keele, United Kingdom, with an additional facility in Södertälje, Sweden, is a leading international contract manufacturing organization (CMO) specializing in biologics and pharmaceuticals for pre-clinical, clinical, and commercial supply. The company offers a comprehensive range of integrated and stand-alone services, including cell line development, GMP cell banking, stability testing, protein characterization, bioassays, analytical services, sterile drug product fill finish, and plasmid DNA services. Cobra Biologics supports the global life sciences industry in developing and manufacturing monoclonal antibodies, recombinant proteins, DNA, viruses, phage, and cell line-derived products for clinical trials and commercial supply. With over 15 years of experience, the company is known for its expertise in producing biologics and pharmaceuticals from pre-clinical to Phase III clinical trials.

Ixaka is a UK-based biotechnology company focused on developing advanced cell-based therapeutics to treat serious diseases. Its proprietary technologies enhance the inherent therapeutic power of cells by targeting curative cells to the site of disease and modifying them within the body to improve their action, with potential applications across oncology, cardiovascular, neurological, ocular diseases, and genetic disorders.

Oxford Biomedica is a biopharmaceutical company focused on gene and cell therapy, specializing in the development, manufacturing, and advancement of lentiviral vector-based medicines and related cell therapies. The company leverages its LentiVector platform to deliver therapeutic genes into non-dividing cells and collaborates with major pharmaceutical firms to progress both internal candidates and externally funded programs. Its internal pipeline targets diseases of the eye and the central nervous system, while ongoing partnerships span multiple therapeutic areas across Phase I/II and beyond. Oxford Biomedica also operates as a contract development and manufacturing organization, offering viral vector development and manufacturing services through OXB Solutions. Founded in 1995 and headquartered in Oxford, United Kingdom, the company maintains a global collaboration network with industry and academic partners.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company that develops a novel class of medicines called Bicycles, synthetic short peptides constrained to form two loops that stabilize their structure. Its lead program BT1718 is a Bicycle Toxin Conjugate for oncology, with Phase I/IIa trials in tumors expressing Membrane Type 1 matrix metalloprotease. The company is also advancing BT5528, a BTC targeting EphA2, and BT8009 in preclinical development for Nectin-4, along with preclinical CD137 and THR-149, a plasma kallikrein inhibitor for diabetic macular edema. Beyond its internal programs, Bicycle Therapeutics collaborates with Cancer Research Technology, Cancer Research UK, AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund, and has a discovery collaboration with Genentech for immuno-oncology targets. The company was founded in 2009 and is headquartered in Cambridge, United Kingdom.

Spoonful of Sugar Ltd. specializes in providing evidence-based adherence solutions for healthcare providers and the life sciences industry. The company focuses on optimizing medication access and enhancing adherence through intelligent medicines engagement programs. By delivering tailored services, Spoonful of Sugar aims to improve stakeholder concordance and overall health outcomes. Their work involves consulting on medicines-related behavior, enabling clients to gain a deeper understanding of the factors that influence medication adherence. Through these initiatives, Spoonful of Sugar seeks to support both healthcare providers and the pharmaceutical industry in achieving better patient care.

Spirea Ltd is a healthcare technology company based in Harrogate, United Kingdom, focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment. Established in 2015, Spirea has created a smart polymer platform that enhances the controlled delivery of drug combinations, aiming to maximize the clinical efficacy of therapies. The company's flexible approach to ADC design allows for a greater amount of drug payload to be precisely targeted at tumor cells, increasing therapeutic effects while significantly minimizing adverse side effects. This advancement enables healthcare providers to offer well-tolerated treatment options for a variety of cancer types, ultimately improving patient outcomes.

CN Bio Innovations Ltd, established in 2008 and headquartered in Cambridge, UK, specializes in developing and providing Organ-on-Chip devices to pharmaceutical and biotech companies. These devices enable more accurate preclinical drug testing by replicating the physiological functions of human organs. CN Bio's offerings include microphysiological systems and consumables, used by various industries to analyze novel compounds, assess toxicity and safety, and support research scientists in investigating biological processes. The company's flagship product, the LiverChip platform, features a full viral lifecycle model of hepatitis B, currently employed in drug discovery collaborations with leading pharma and biotech firms. CN Bio, part of Hong Kong-based CN Innovations Holdings Limited, works closely with academic experts and is backed by prestigious grants, aiming to accelerate the development of transformative therapies worldwide.